Hypnogen

Zolpidem, the active ingredient in Hypnogen, is a non‑benzodiazepine hypnotic presented as an oral tablet for oral use. It is indicated for short‑term treatment of insomnia in adults, helping to initiate and maintain sleep, and is classified under the imidazopyridine class.

GNH USA supplies Hypnogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable sourcing for regulated markets.

Zolpidem is used to manage sleep disorders within the insomnia therapeutic area.

- Insomnia (short‑term treatment): improves sleep onset and maintenance in adults. - Sleep onset insomnia: reduces the time required to fall asleep. - Sleep maintenance insomnia: decreases the number of nocturnal awakenings and prolongs total sleep time.

Zolpidem may cause a range of adverse reactions, from mild to serious. Patients should be aware of both common and less frequent side effects.

Common Side Effects: - Drowsiness - Dizziness - Headache - Dry mouth

Serious or Rare Side Effects: - Complex sleep behaviours (e.g., sleep‑walking, sleep‑driving) - Allergic reactions (rash, swelling, anaphylaxis) - Depression or worsening mood, including suicidal thoughts

When prescribing Zolpidem, clinicians should consider several safety measures to minimise risk.

- Assess sleep history: ensure use is limited to short‑term therapy. - Avoid alcohol: concurrent use may intensify central nervous system depression. - Monitor for complex sleep behaviours: advise patients to report unusual activities performed while not fully awake. - Caution in hepatic impairment: reduced clearance may require dose adjustment. - Pregnancy and lactation: use only if potential benefits outweigh potential risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Zolpidem interacts with several drug classes; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Alcohol: additive central nervous system depression. - Opioids: increased risk of respiratory depression. - Other CNS depressants (e.g., antihistamines, antipsychotics): heightened sedation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise zolpidem plasma concentrations. - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Fluoxetine: can increase risk of side effects by inhibiting metabolism.